Navigation Links
Medasense Receives Patent Approval for Novel Pain-Monitoring System
Date:8/20/2013

Tel Aviv, Israel (PRWEB) August 20, 2013

Medasense Biometrics Ltd. announced today it has received U.S. patent approval for its novel system and multi-parameter method of assessing the pain level of patients in various states of consciousness. (U.S. Patent No. 8,512,240 – “System and Method for Pain Monitoring Using a Multidimensional Analysis of Physiological Signals.”)

Medasense’s innovative technology enables non-invasive, objective, pain monitoring by measuring multiple pain-related physiological parameters. The data is then integrated using state-of-the-art signal processing and pattern recognition algorithms to identify a patient’s unique “signature of pain.” Using this information, physicians can adapt pain medications to patient-specific needs to reduce suffering and improve treatment outcomes.

“Pain is now widely considered the fifth vital sign,” says Galit Zuckerman, founder and CEO of Medasense. “Our easy-to-use system adds objective pain measurement to the array of technically advanced patient-monitoring tools already used in critical care, anesthesia and recovery, and similar environments.”

Medasense’s successfully completed clinical studies verify the system’s ability to accurately measure pain response and demonstrate that it outperforms all existing pain indicators. “Receiving this patent approval is a milestone achievement for the Medasense team,” says Zuckerman. “We look forward to providing physicians with a much better way to monitor and manage patient pain.”

About Medasense
Medasense Biometrics Ltd. is an early-stage medical device company specializing in innovative pain monitoring solutions. The company’s automated pain-monitoring system is designed to provide a continuous, highly accurate assessment of a patient’s pain level. Medasense is financed and supported by both private investors and by Medoc Ltd., a prominent manufacturer of pain diagnostic medical systems. For more information, visit: http://www.medasense.com/.

CONTACT:
Nir Ben Israel
Medasense Biometric Ltd.
info(at)medasense(dot)com
Tel. 972-4-9038800

Read the full story at http://www.prweb.com/releases/2013/8/prweb11038757.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. UCSB professor receives award for graphene electronics research
2. Watsons Generic Yaz(R) Receives FDA Approval
3. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
4. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
5. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
6. Intimate Bridge 2 Conception, Inc. Receives $4.3M
7. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
8. BioNeutral Group Receives $400,000 in Equity Financing
9. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
10. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
11. Life Technologies Receives AFNOR Validation for Tests Designed to Detect Listeria Contamination in Food Samples
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... , ... March 22, 2017...Council for Agricultural Science and Technology, Ames, Iowa. ... innovation in smart, sustainable ways. Humans depend on plants for food, feed, fiber, and ... This paper is the first in a series that connects science and technology to ...
(Date:3/22/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced Alexey ... present at the 5th Annual Cancer BioPartnering & ... to present to and meet with thought leaders ... companies as well as institutional investors. This event ...
(Date:3/20/2017)... Diego, CA (PRWEB) , ... ... ... (EDCs) are substances that interfere with the ability of endogenous hormones to ... or inhibiting ligand binding activity (antagonists), EDCs produce adverse reproductive, neurological, proliferative, ...
(Date:3/20/2017)... (PRWEB) , ... March 20, 2017 , ... ... expensive and laborious sample preparation methods in order to reduce the impact on ... outside of the area of elemental analysis. , This presentation will discuss ...
Breaking Biology Technology:
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
Breaking Biology News(10 mins):